Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Hospices Civils de Lyon, Lyon, France

Survival: 12.1 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: France
City/State/Province: Lyon
Hospital: Hospices Civils de Lyon
Journal: Link
Date: 10/2012

This phase 3 study involved patients with advanced non-small-cell lung cancer patients, previously treated with cisplatin and gemcitabine, who were divided into two treatment groups. Group A consisted of 154 patients with a median age of 57.9 years and 73.4% male. Group B had 155 patients with a median age of 56.4 years and 72.9% male.

Patients in group A were treated with the chemotherapy agent gemcitabine.

Patients in group B were treated with the biologic therapy agent erlotinib, which blocks tumor cell growth by inhibiting a protein called EGFR.

There were two treatment-related deaths in group A due to pneumonia and kidney failure. Grade 3-4 neutropenia, thrombocytopenia, and anemia were also reported.

The most severe toxicities in group B were of grade 4. Grade 3-4 toxicities included rash, infection, and pneumonia.

The median overall survival was 12.1 months for group A and 11.4 months for group B.

This study was partially supported by the pharmaceutical companies Roche and Eli Lilly.

Correspondence: Dr. Maurice Perol; email:

E-mail to a Friend Email Physician More Information